944805-93-0

Basic information

• Product Name: (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID
• Synonyms: (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID;RARECHEM AL BK 1231;(2E)-3-[6-(Trifluoromethyl)pyridin-3-yl]prop-2-enoic acid, trans-3-[6-(Trifluoromethyl)pyridin-3-yl]acrylic acid;(E)-3-[6-(Trifluoromethyl)pyridin-3-yl]acrylic acid
• CAS NO: 944805-93-0
• Molecular Formula: C9H6F3NO2
• Molecular Weight: 217.14
• Mol File: 944805-93-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 232-236°C
• Boiling Point: 284.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.430±0.06 g/cm3(Predicted)
• PKA: 3.56±0.10(Predicted)
• CAS DataBase Reference: (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID(944805-93-0)
• EPA Substance Registry System: (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID(944805-93-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 944805-93-0(Hazardous Substances Data)

Usage

Description

(2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID is a chemical compound characterized by a pyridine ring with a trifluoromethyl group at the 6th position and a propenoic acid group at the 3rd position. This unsaturated carboxylic acid is notable for its potential in the pharmaceutical industry, particularly in the synthesis of drugs. The presence of the trifluoromethyl group is advantageous as it can improve the bioavailability and metabolic stability of resulting pharmaceutical compounds. The propenoic acid functional group adds to its versatility, allowing for various chemical modifications and synthetic pathways to generate new drug candidates. This makes (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID a valuable component in medicinal chemistry and drug discovery.

Uses

Used in Pharmaceutical Industry:
(2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to enhance bioavailability and metabolic stability. The trifluoromethyl group attached to the pyridine ring is known to improve these properties, which is crucial for the effectiveness and safety of drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID serves as a versatile building block for the development of new drug candidates. The propenoic acid functional group allows for a range of chemical modifications, facilitating the creation of diverse and innovative pharmaceutical agents.
Used in Drug Discovery:
(2E)-3-[6-(TRIFLUOROMETHYL)PYRIDIN-3-YL]PROPENOIC ACID is utilized in drug discovery processes to explore its potential in forming new molecules with therapeutic effects. Its unique structure and functional groups make it a promising candidate for the development of novel treatments for various diseases and conditions.

Upstream product

• 386704-12-7 6-(trifluoromethyl)pyridine-3-carbaldehyde 
• 436799-32-5 5-bromo-2(trifluoromethyl)pyridine 
• 79-10-7 acrylic acid 
• 539855-70-4 3-(6-trifluoromethyl-pyridin-3-yl)-propionic acid 

Relevant articles and documents

Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via C–H activation

Dehydrogenative transformations of alkyl chains to alkenes through methylene carbon-hydrogen (C–H) activation remain a substantial challenge. We report two classes of pyridine-pyridone ligands that enable divergent dehydrogenation reactions through palladium-catalyzed b-methylene C–H activation of carboxylic acids, leading to the direct syntheses of a,b-unsaturated carboxylic acids or g-alkylidene butenolides. The directed nature of this pair of reactions allows chemoselective dehydrogenation of carboxylic acids in the presence of other enolizable functionalities such as ketones, providing chemoselectivity that is not possible by means of existing carbonyl desaturation protocols. Product inhibition is overcome through ligand-promoted preferential activation of C(sp3)–H bonds rather than C(sp2)–H bonds or a sequence of dehydrogenation and vinyl C–H alkynylation. The dehydrogenation reaction is compatible with molecular oxygen as the terminal oxidant.

Synthesis of novel tetrahydroisoquinoline bronchodilators

The synthesis and bronchorelaxing effects of a series of novel tetrahydroisoquinoline amides are described. The compounds were evaluated for their ability to relax LTD4 contracted isolated human small airways ex-vivo. Several compounds demonstrated highly

Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides

The vanilloid receptor-1 (TRPV1 or VR1) is a member of the transient receptor potential (TRP) family of ion channels and plays a role in regulating the function of sensory nerves. A growing body of evidence demonstrates the therapeutic potential of TRPV1 modulators, particularly in the management of pain. As a result of our screening efforts, we identified (E)-3-(4-tert- butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (1), an antagonist that blocks the capsaicin-induced and pH-induced uptake of 45Ca2+ in TRPV1-expressing Chinese hamster ovary cells with IC50 values of 17 ± 5 and 150 ± 80 nM, respectively. In this report, we describe the synthesis and structure-activity relationship of a series of N-aryl cinnamides, the most potent of which (49a and 49b) exhibit good oral bioavailability in rats (Foral = 39% and 17%, respectively).